Close

Baird Upgrades ResMed (RMD) to Outperform

Go back to Baird Upgrades ResMed (RMD) to Outperform

ResMed (RMD) Receives Two Wall Street Upgrades as Rival Philips Deals with Expanded Recalls

January 13, 2022 9:04 AM EST

ResMed (NYSE: RMD) shares were upgraded by two separate analysts Thursday as the company is seen as a beneficiary to rival Philips' expanded CPAP, BiPAP and Mechanical Ventilator recall from 4 million to 5.2 million devices, while it only has about 1.5 million repair and replace... More

ResMed (RMD) PT Raised to $234 at RBC Capital on More Philips Woes

January 13, 2022 7:32 AM EST

RBC Capital analyst Craig Wong-Pan raised the price target on ResMed (NYSE: RMD) to $234.00 (from $227.00) while maintaining an Underperform rating after rival Philips recalled expanded to 5.2 million devices "and the cadence of manufacturing repair kits and replacement devices was slightly slower than we expected."

... More